Articles from Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 3:45 p.m. Pacific Time.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in three upcoming investment conferences.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for aggregate gross proceeds of approximately $50 million.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2024.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has published its 2024 Post Market Surveillance (PMS) Report.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that the first patients in the United States have successfully undergone breast augmentation with Motiva® Implants.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2024.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results at The Aesthetic Meeting 2024 in Vancouver, BC Canada.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Establishment Labs Holdings Inc. (NASDAQESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China.

Establishment Labs Holdings Inc. (NASDAQESTA) (“Establishment Labs” or the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a securities purchase agreement with select institutional accredited investors to purchase common shares of the Company, or pre-funded warrants in lieu thereof. The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. Pacific Time.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has received National Medical Products Administration (NMPA) approval in China for Motiva® Implants.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2023.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended Semptember 30, 2023, after the market closes on Tuesday, November 7, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today both the two-year clinical results of Mia Femtech™ as well as its launch of Zen™, the Company’s next generation RFID technology, at the 8th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Lisbon, Portugal.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2023.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the grand opening of the Sulàyöm Innovation Campus in the Coyol Free Zone, Costa Rica.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investor conferences.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has received CE marking under the European Medical Device Regulation for the Motiva Injector®, the Motiva® Inflatable Balloon, and the Motiva® Channel Dissector.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2023.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the closing of its previously announced public offering of 1,265,000 common shares at $71.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 165,000 additional common shares. The gross proceeds to the Company were approximately $90.4 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2023 after the market closes on Monday, May 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the pricing of its public offering of 1,100,000 common shares at a price of $71.50 per share. The gross proceeds to Establishment Labs, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $78.7 million. The offering is scheduled to close on April 27, 2023, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to 165,000 additional common shares, at the public offering price per share, less underwriting discounts and commissions.

Establishment Labs Holdings Inc. (NASDAQESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has commenced a public offering of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares to be sold in the proposed offering, at the public offering price per share, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Establishment Labs Holdings Inc. (NASDAQESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the first quarter of 2023.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today noted the presentation of a study update on the Motiva US IDE Study. The update included three-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also a Principal Investigator in the Study, presented the results today at Aesthetic Surgery Education and Research Foundation (ASERF) Premier Global Hot Topics session as part of The Aesthetic Meeting 2023 in Miami, Florida.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the launch of Mia Femtech™ (“Mia®”) in Japan, marking the beginning of a new era in breast aesthetics.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2023, which is being held April 19-23 in Miami, Florida.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva® devices in market.

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech™ (“Mia®”).

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 am Eastern Time.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States. The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022 and provided 2023 guidance.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2022, after the market closes on Monday, February 27, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited revenue for the three months and fiscal year ended December 31, 2022.

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into an agreement with Seishin Plastic and Aesthetic Surgery Clinic in Japan for Mia Femtech™ (“Mia®”).

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 7:30 a.m. Pacific Time.

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced Motiva Implants® and the Motiva Flora® tissue expander have been approved for use in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA). The products have also received reimbursement for post-mastectomy reconstruction under the Japanese National Health System. The first reconstruction patient in Japan was successfully treated with Motiva in early November at Nagoya University Hospital.

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the third quarter ended September 30, 2022.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2022 after the market closes on Monday, November 7, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it will host an investor event on October 5, 2022 to discuss Mia Femtech® (“Mia”). A webcast of the event will begin at 4:30 p.m. Eastern Time.

Establishment Labs Holdings Inc. (NASDAQESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has retained Hani Zeini to an exclusive, multiyear advisory contract in anticipation of its US commercial launch.

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the second quarter ended June 30, 2022.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has completed enrollment in the Motiva US IDE clinical study. The final surgery in the primary reconstruction cohort was completed at Northwestern Memorial Hospital. The Augmentation cohort, which finished enrollment in August of 2019, will complete its third year of study follow-up this month.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2022 after the market closes on Monday, August 8, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced publication of its 2021 Sustainability Review to coincide with the fourth anniversary of the company’s public listing on NASDAQ.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 am Eastern Time.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the first quarter ended March 31, 2022.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2022 after the market closes on Monday, May 9, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has entered into a $225 million term loan financing facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

Establishment Labs Holdings Inc. (NASDAQESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today noted the presentation of interim study data from the augmentation cohort of its Motiva US IDE Study. This Study Update includes two-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also a Principal Investigator in the Study, is presenting the results today at The Aesthetic Meeting 2022 in San Diego, California.

Establishment Labs Holdings Inc. (NASDAQESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its participation in The Aesthetic Meeting 2022, which is being held April 20-24 in San Diego, California, as well as sessions of interest at the meeting.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed two million Motiva Implants® in market.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2021 before the market opens on Tuesday, March 1, 2022, and will host a conference call at 8:30 am ET that day to discuss those results.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today reported preliminary unaudited revenue for the three months and fiscal year ended December 31, 2021.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30pm Eastern Time.

Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Raj Denhoy as Chief Financial Officer effective immediately. Mr. Denhoy has been with the company since February 2021, including as Interim Chief Financial Officer since August.